Beam Therapeutics’ experimental gene-editing therapy for sickle cell disease now has its first cut of patient data showing signs of treating the rare blood disorder in a way that could differentiate ...
A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...
Add Yahoo as a preferred source to see more of our stories on Google. Futuristic 3D cubes showing DNA base pairs and a double helix. (Getty Images) This story was originally published on BioPharma ...
Beam Therapeutics BEAM announced that the FDA has granted an orphan drug designation to its investigational genome-editing candidate, BEAM-101, for the treatment of sickle cell disease (SCD), an ...
On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell ...
ROCHESTER — When Derek Gerlach, then 10 years old, was diagnosed with stage 4 brain cancer in November 2018, his treatment began almost immediately. Within a month, Derek underwent surgery to remove ...
Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results